FFPE samples from 9 stage III/IV melanomas, 10 stage I/II melanomas, 4 dysplastic nevi, 10 melanocytic nevi and 4 patients before and after BRAF inhibitor treatment. This evidence concerns the gene BRAF and dysplastic nevus.